|
Symposium
[Free Online Symposium] Diagnostic Tools, Therapeutics and Vaccines for COVID-19: An Overview and Forward Analysis
Speakers:
Kevin Grimes, MD (Professor, Stanford University), John Sninsky, PhD (Consultant in Translational Science and Medicine), Ian Villamagna, PhD (Precision Nanosystems) and Stephen Rabinowitz, D.Phil (Partner, Dechert LLP)
Organizers:
Shichang Miao and John Sninsky
Date:
2020-08-18
Time:
9:00-11:00 Pacific Time
Registration fee:
(USD): Regular: $0
Location:
Online via Zoom by PBSS-SFBay
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2020-08-16
(it will close sooner if the seating cap is reached)
About the Topic
A once in a century pandemic, COVID-19, highlights in sharp contrast the deficiency in translation between innovation and clinical implementation to improve patient management. This online minisymposium will summarize the challenges and regulatory science considerations for rapidly transitioning diagnostics and developing or repurposing drugs in a pandemic. In addition, the intellectual property framework to accommodate the urgent needs of a pandemic while retaining incentives to stimulate future research and the creation of new diagnostics and medicines will be discussed.
Tues, August 18, 2020 Agenda
9:00 am - 9:05 am Welcome & Introduction - Shichang Miao, PhD (President, PBSS)
9:05 am - 9:30 am Challenges and opportunities of COVID-19 diagnostics - John J. Sninsky, PhD (Consultant in Translational Science and Medicine)
9:30 am - 9:50 am Drug repurposing: de-risked drugs for new indications - Kevin Grimes, MD (Professor, Stanford University)
9:50 am – 10:00 am Major Sponsor's Presentation - QPS
10:00 am – 10:15 am Break
10:15 am - 10:40 am RNA Nanovaccines: non-viral delivery - Ian Villamagna, PhD (Precision Nanosystems)
10:40 am - 11:00 am Patents in a pandemic - Stephen Rabinowitz, MD, PhD, JD (Partner, Dechert LLP)
11:00 am - 11:30 am Q&A and Close
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Submit a Text Ad
|